← boardnext 2026-08-19next 2029-03-02
SYRE
Spyre Therapeutics, Inc.distress 6/10 · elevated risk$97.85-1%today-5% from 52w high
Immunology / Inflammation 1
Lead: ulcerative colitis · target a4b7 · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$97M
Runway
0.5 yrs
Shares 1y
+44%
Price & events
+187.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
+4.0%
1W
+0.8%
1M
+41.3%
3M
+205.4%
6M
+449.4%
1Y
+207.4%
2Y
-40.3%
5Y
-54.3%
All
Overview
- Market Cap
- $8.50B
- Volume
- 31.52K
- 52 Week Range
- $14.82 – $103
- Total Shares
- 86.84M
- Float Shares
- 81.05M
- Short %
- 16.81%
- % Held by Insiders
- 5.86%
- % Held by Institutions
- 93.27%
- RVOL
- 0.02x
- Beta
- 3.02
Pipeline stages · 2 programs
SPY002-072
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SPY001, SPY002, SPY003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-19 Estimated 50% readout ~2026-09-18 final ~2026-11-30 | Phase 1 | SPY002-091 | Healthy | 50 | active not recruiting |
| 2026-10-31 Estimated 50% readout ~2026-12-15 | Phase 2 | SPY002-072 | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease | — | active not recruiting |
| 2029-03-02 Estimated 50% readout ~2029-04-16 | Phase 2 | SPY001, SPY002, SPY003 | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | — | enrolling by invitation |
| 2026-06 | Phase 2 | SPY001, SPY002, SPY003 | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | recruiting |
| 2026-04-03 | Phase 1 | SPY002-072 | Healthy | 56 | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03-10 | Phase 1 | SPY001-001 | Healthy | 96 | completed |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 21
- 2027Guided 40%readoutPhase 2SKYLINE Part B (multiple cohorts) · Induction data for all cohorts in Part B of SKYLINE trialSEC 8-K
- 2027Guided 40%readoutPhase 2SPY001, SPY002, SPY003 · Placebo-controlled induction data from SKYLINE-UC Part B.SEC 8-K
- 2026Guided 40%readoutPhase 2SPY003 · Data readouts from Phase 2 basket (SKYWAY) and platform (SKYLINE) trials expected in 2026.SEC 8-K
- 2026Guided 40%readoutPhase 2SPY002 · Topline results for Phase 2 RA trialSEC 8-K
- 2026Guided 40%readoutPhase 2SPY001, SPY002, SPY003 · Open-label monotherapy induction data from SKYLINE-UC Part A.SEC 8-K
- 4Q 2026Guided 70%readoutPhase 2SPY072 · Proof-of-concept readoutSEC 8-K
- Q3 2026Guided 70%readoutPhase 2SPY003 · Proof-of-concept induction data for SPY003 from SKYLINE Part ASEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutPhase 2SPY002 · Part A proof-of-concept readoutSEC 8-K
- Q2 2026readoutPhase 2SPY003 · Part A proof-of-concept readoutSEC 8-K
- Q2 2026readoutPhase 2SPY001 · Part A proof-of-concept readoutSEC 8-K
- 2026-05-29partnershipSPY003 · Expanded field of use to all indications; dosing restrictions for non-IBD combination trials until 2028 and monotherapy until 2030.SEC 8-K
- in 2025conferencedata presentationsecondaryPhase 1SPY001 · Longer-term Phase 1 data at a medical meetingSEC 8-K
- 2H2025readoutPhase 1SPY003 · Phase 1 interim dataSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 2SPY072 · Initiation of SKYWAY-RD Phase 2 basket trial.SEC 8-K
- mid-2025trial initiationsecondaryPhase 2SPY001, SPY002, SPY003 · Plan to initiate Phase 2 platform trial in moderately-to-severely active ulcerative colitisSEC 8-K
- mid-2025trial initiationsecondaryPhase 2SPY002 · Phase 2 RA trial initiationSEC 8-K
- 2Q2025readoutPhase 1SPY002 · Phase 1 interim results for both anti-TL1A moleculesSEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1SPY003 · First-in-human dosing of SPY003 in healthy volunteersSEC 8-K
- 1Q2025readoutPhase 1SPY003 · Phase 1 initiationSEC 8-K
- 2024-10-11partnershipSPY003 · License agreement with Paragon for anti-IL-23 antibodies in IBDSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $104 (+6% upside) · 15 analysts
- 2026-07-13MizuhoOutperform
- 2026-06-23Deutsche BankBuy
- 2026-06-15BTIGBuy
- 2026-06-04Deutsche BankBuy
- 2026-05-06StifelBuy
- 2026-05-06CitigroupBuy
Competitors — a4b7
- none identified
Recent news
- 2026-07-17SYRE Stock Draws Analyst Upgrades As Volatility Spikes - StocksToTrade
- 2026-07-14Spyre Therapeutics stock hits 52-week high at 102.46 USD - Investing.com
- 2026-07-13Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating - marketscreener.com
- 2026-07-11SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
- 2026-07-10Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
- 2026-07-10Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - Sahm
- 2026-07-07Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
- 2026-07-02Spyre Therapeutics (SYRE) CEO trims stake in 15,000-share 10b5-1 sale - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.